Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Go-Gold, TheHungryHippo, BluSkies, GoldenMind, StemCellJunkie
Search This Board: 
Last Post: 12/16/2017 3:47:59 PM - Followers: 791 - Board type: Free - Posts Today: 8


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 11/07/2017 04:04:52 PM
USRM News: Current Report Filing (8-k) 09/13/2017 09:01:32 AM
USRM News: Initial Statement of Beneficial Ownership (3) 09/01/2017 04:06:18 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:04:29 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:02:44 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#84681  Sticky Note FDA created guidelines for stem cell regulation. NoMoDo 11/28/17 03:04:46 PM
#84213  Sticky Note MUST READ: After some heavy research I came StemCellJunkie 11/22/17 07:13:38 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#78232  Sticky Note Official response to FDA Warning Letter. Deal McMogulson 08/29/17 02:42:32 PM
#85903   loads of paper going digital too...coins a popping. rocketRider 12/16/17 03:47:59 PM
#85900   It is just day Traders exiting. They buy 0mn1 12/16/17 02:03:51 PM
#85899   Market value question. 3 or 4 weeks ago Eldeano57 12/16/17 01:56:33 PM
#85895   I hear ya wolf I’m just chilling grabbing Rinkydink 12/15/17 10:54:07 PM
#85894   We should not be so concerned with the Lonewolf1 12/15/17 08:55:18 PM
#85893   Amen this manipulation is REAL too bad US Rinkydink 12/15/17 08:45:51 PM
#85892   Yes sir! A leader in regenerative medicine and MyzStreet 12/15/17 07:44:40 PM
#85891   They said they would look out for new Neco batmaz 12/15/17 04:22:11 PM
#85890   I could be wrong but I’ll say the Cdizz123 12/15/17 04:03:37 PM
#85889   That is absurd NoMoDo 12/15/17 04:00:28 PM
#85888   Looking forward to a green week next week! TruthSpeaker12 12/15/17 03:59:23 PM
#85887   Quote LOL, "According to the fda web site, Hornet Driver 12/15/17 03:58:33 PM
#85885   Because it is being manipulated. Why does NoMoDo 12/15/17 03:42:02 PM
#85884   According to the fda web site, a warning NoMoDo 12/15/17 03:33:02 PM
#85883   FDA Comella/USCC "WARNING LETTER" SERIOUS...uh oh.. Hornet Driver 12/15/17 03:28:34 PM
#85882   FAT STEM CELLS ARE "DRUGS" CASE CLOSED, GAME Hornet Driver 12/15/17 03:21:59 PM
#85881   Myocell NO LONGER EVEN UNDER PATENT..uh.. Hornet Driver 12/15/17 03:19:42 PM
#85880   WHy is it priced below all the other Cdizz123 12/15/17 03:18:49 PM
#85879   Power hour - time for MMs to load Lonewolf1 12/15/17 03:05:06 PM
#85878   This is a $14 billion industry and USRM NoMoDo 12/15/17 02:59:44 PM
#85877   Sponsors of drugs that have been granted accelerated NoMoDo 12/15/17 02:56:59 PM
#85876   No it isn't. NoMoDo 12/15/17 02:50:10 PM
#85875   If partnership is found to pursue RMAT, once docprep 12/15/17 02:46:05 PM
#85874   That’s pretty optimistic considering phase 4 is long Rinkydink 12/15/17 02:33:21 PM
#85873   I bet we touch .07 then drop to NoMoDo 12/15/17 02:23:28 PM
#85872   Thank God high volume January is bout here$$$$$ TooYoungToDie 12/15/17 02:04:31 PM
#85871   Lol idk about teens without news of partnership Rinkydink 12/15/17 01:48:47 PM
#85870   Look we all want same thing. I don't docprep 12/15/17 01:45:00 PM
#85869   Yep that’s why I’ve been adding I doubt Rinkydink 12/15/17 01:44:21 PM
#85868   It’s also different for those who have no Rinkydink 12/15/17 01:41:46 PM
#85867   Dip rip zip zip. I think this is Neco batmaz 12/15/17 01:40:13 PM
#85866   That’s the talk of the impatient investor tho Rinkydink 12/15/17 01:37:11 PM
#85865   .034 -.035 is the dip. 04 and docprep 12/15/17 01:35:42 PM
#85864   And that’s the thing .034 is averaging up Rinkydink 12/15/17 01:32:48 PM
#85863   So let's just give up them..throw in towel? docprep 12/15/17 01:31:24 PM
#85862   And for what so they can bring it Rinkydink 12/15/17 01:30:43 PM
#85861   If you're sitting on 300k shares at .04. docprep 12/15/17 01:30:04 PM
#85860   Lol why pay more when you can pay Rinkydink 12/15/17 01:27:58 PM
#85859   People in here spend too much time bid docprep 12/15/17 01:25:36 PM
#85858   Let em put up a big share wall Rinkydink 12/15/17 01:23:36 PM
#85857   Slap ask...force spread to close...upwards docprep 12/15/17 01:23:07 PM
#85856   I wouldn’t sell at .07 either these 15%+ Rinkydink 12/15/17 01:22:26 PM
#85855   If you wait til EOD, they'll stack the docprep 12/15/17 01:21:14 PM
#85854   Ok I’ll slap a tiny end of dayer Rinkydink 12/15/17 01:18:50 PM
#85853   Why have an ask under .07...selling for less docprep 12/15/17 01:18:40 PM
#85852   Nice to see that NASDAQ biotech index stock docprep 12/15/17 01:17:19 PM
#85851   Oh my ask is raised no question there Rinkydink 12/15/17 01:17:15 PM
#85850   Apparently...and bids aren't being filled. Raise both, see docprep 12/15/17 01:07:50 PM
#85849   It’s probably a mistake Cdizz123 12/15/17 01:02:44 PM
#85848   Only a couple asks below .04 gee maybe Rinkydink 12/15/17 12:49:35 PM